Item 8.01. Other Events.
On January 4, 2018, AveXis, Inc. (the Registrant) issued a press release to provide an update following the receipt of minutes from the Registrants end-of-Phase 1 meeting with the U.S. Food and Drug Administration conducted on December 5, 2017, regarding the Registrants primary gene therapy candidate, AVXS-101, for the treatment of spinal muscular atrophy Type 1. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.